GlycoMimetics Reports Phase 3 Uproleselan Trial Success
Company Announcements

GlycoMimetics Reports Phase 3 Uproleselan Trial Success

GlycoMimetics (GLYC) has issued an update.

GlycoMimetics, Inc. announced significant findings from its Phase 3 trial of uproleselan, targeting relapsed/refractory acute myeloid leukemia, and held a live webcast to discuss these outcomes. While detailed results were shared, this information is for disclosure purposes and will not be considered officially filed or integrated into prior or future securities filings, unless explicitly stated.

Find detailed analytics on GLYC stock on TipRanks’ Stock Analysis page.

Related Articles
Howard KimIs GLYC a Buy, Before Earnings?
TheFlyGlycoMimetics options imply 8.8% move in share price post-earnings
TheFlyBiotech Alert: Searches spiking for these stocks today
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App